EyePoint Pharmaceuticals (EYPT) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

EyePoint Pharmaceuticals Revenue Highlights


Latest Revenue (Y)

$46.02M

Latest Revenue (Q)

$9.48M

Main Segment (Y)

Y U T I Q Product

Main Geography (Y)

UNITED STATES

EyePoint Pharmaceuticals Revenue by Period


EyePoint Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$46.02M11.14%
2022-12-31$41.40M12.09%
2021-12-31$36.94M7.27%
2020-12-31$34.44M69.10%
2019-12-31$20.36M587.77%
2018-06-30$2.96M-60.72%
2017-06-30$7.54M365.37%
2016-06-30$1.62M-93.90%
2015-06-30$26.57M664.90%
2014-06-30$3.47M62.06%
2013-06-30$2.14M-39.22%
2012-06-30$3.53M-28.98%
2011-06-30$4.96M-78.46%
2010-06-30$23.05M89.55%
2009-06-30$12.16M249.88%
2008-06-30$3.48M55.53%
2007-06-30$2.23M52.52%
2006-06-30$1.47M132.78%
2005-06-30$629.52K137.35%
2004-06-30$265.23K256.73%
2003-06-30$74.35K-85.60%
2002-06-30$516.32K-

EyePoint Pharmaceuticals generated $46.02M in revenue during NA 2023, up 11.14% compared to the previous quarter, and up 1554.14% compared to the same period a year ago.

EyePoint Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$9.48M-18.89%
2024-03-31$11.68M-16.71%
2023-12-31$14.03M-7.72%
2023-09-30$15.20M66.96%
2023-06-30$9.11M18.51%
2023-03-31$7.68M-27.06%
2022-12-31$10.53M5.20%
2022-09-30$10.01M-13.43%
2022-06-30$11.56M24.44%
2022-03-31$9.29M-19.49%
2021-12-31$11.54M27.43%
2021-09-30$9.06M0.51%
2021-06-30$9.01M23.08%
2021-03-31$7.32M2.69%
2020-12-31$7.13M-54.57%
2020-09-30$15.70M280.76%
2020-06-30$4.12M-44.96%
2020-03-31$7.49M-13.25%
2019-12-31$8.63M244.08%
2019-09-30$2.51M-65.20%
2019-06-30$7.21M258.35%
2019-03-31$2.01M-17.61%
2018-12-31$2.44M402.47%
2018-09-30$486.00K-32.03%
2018-06-30$715.00K-22.95%
2018-03-31$928.00K-0.54%
2017-12-31$933.00K142.34%
2017-09-30$385.00K-45.08%
2017-06-30$701.00K18.81%
2017-03-31$590.00K-90.12%
2016-12-31$5.97M2055.60%
2016-09-30$277.00K-8.88%
2016-06-30$304.00K-6.17%
2016-03-31$324.00K-38.40%
2015-12-31$526.00K12.88%
2015-09-30$466.00K13.94%
2015-06-30$409.00K24.70%
2015-03-31$328.00K-37.04%
2014-12-31$521.00K-97.94%
2014-09-30$25.31M8566.78%
2014-06-30$292.00K-85.34%
2014-03-31$1.99M236.49%
2013-12-31$592.00K-0.84%
2013-09-30$597.00K21.34%
2013-06-30$492.00K-4.09%
2013-03-31$513.00K-12.31%
2012-12-31$585.00K5.79%
2012-09-30$553.00K-20.89%
2012-06-30$699.00K29.93%
2012-03-31$538.00K-14.60%
2011-12-31$630.00K-62.03%
2011-09-30$1.66M-55.34%
2011-06-30$3.71M931.94%
2011-03-31$360.00K-13.04%
2010-12-31$414.00K-13.03%
2010-09-30$476.00K-96.97%
2010-06-30$15.72M2952.82%
2010-03-31$515.00K-85.00%
2009-12-31$3.43M1.48%
2009-09-30$3.38M4.96%
2009-06-30$3.22M1.90%
2009-03-31$3.16M6.50%
2008-12-31$2.97M5.84%
2008-09-30$2.81M3.81%
2008-06-30$2.70M398.71%
2008-03-31$542.00K-

EyePoint Pharmaceuticals generated $9.48M in revenue during Q2 2024, up -18.89% compared to the previous quarter, and up 123.35% compared to the same period a year ago.

EyePoint Pharmaceuticals Revenue Breakdown


EyePoint Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19
Y U T I Q Product$28.33M$16.96M$13.88M$12.05M
D E X Y C U Product$11.58M$18.35M$6.95M$4.78M

EyePoint Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Y U T I Q Product (70.99%), and D E X Y C U Product (29.01%).

Quarterly Revenue by Product

Product/ServiceJun 24Sep 23Jun 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Product$1.07M$816.00K$5.27M$11.19M$8.59M$8.74M$6.68M$5.76M$3.71M$6.71M$543.00K--------
Y U T I Q Product$1.10M$9.02M$7.27M$7.42M$4.61M$5.83M$3.93M$4.17M$3.03M$3.96M$3.47M$2.88M$4.74M$55.00K$6.71M----
License And Collaboration Agreement$7.78M$14.14M$3.60M$202.00K---------------
Royalty$627.00K$249.00K$235.00K$474.00K---------------
Collaborative Research And Development-----$15.00K-------------
D E X Y C U Product---$833.00K$2.45M$3.90M$4.40M$5.35M$4.66M$4.57M$3.77M$2.72M$2.29M$827.00K$3.14M$954.00K$684.00K--

EyePoint Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License And Collaboration Agreement (73.57%), Y U T I Q Product (10.40%), Product (10.10%), and Royalty (5.93%).

EyePoint Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20Dec 19Jun 18
CHINA$823.00K$851.00K$11.71M$1.12M-
UNITED STATES$40.48M$35.99M$22.62M$19.14M$2.86M

EyePoint Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (98.01%), and CHINA (1.99%).

Quarterly Revenue by Country

CountryDec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
D E X Y C U Product$833.00K$2.45M$3.90M$4.40M$5.35M$4.66M$4.57M$3.77M$2.72M$2.29M$827.00K$3.14M$954.00K$684.00K--
License And Collaboration Agreement$202.00K---------------
Collaborative Research And Development--$15.00K-------------
Y U T I Q Product$9.02M$7.27M$7.42M$4.61M$5.83M$3.93M$4.17M$3.03M$3.96M$3.47M$2.88M$4.74M$55.00K$6.71M--
Royalty$474.00K---------------
Product----$11.19M$8.59M$8.74M$6.68M$5.76M$3.71M$6.71M$543.00K----

EyePoint Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 22: Y U T I Q Product (85.67%), D E X Y C U Product (7.91%), Royalty (4.50%), and License And Collaboration Agreement (1.92%).

EyePoint Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
IPHAInnate Pharma$51.90M$16.56M
EYPTEyePoint Pharmaceuticals$46.02M$9.48M
HOOKHOOKIPA Pharma$20.13M-
OCUPOcuphire Pharma$19.05M-
MREOMereo BioPharma Group$10.00M-
HCWBHCW Biologics$2.84M$618.85K
OBIOOrchestra BioMed$2.76M$778.00K
CMRXChimerix$324.00K$129.00K
ALXOALX Oncology--
XFORX4 Pharmaceuticals-$563.00K
CABACabaletta Bio--
RVPHReviva Pharmaceuticals--
DAWNDay One Biopharmaceuticals-$20.07M
ABOSAcumen Pharmaceuticals--
VIRXViracta Therapeutics--
BMEABiomea Fusion--
TERNTerns Pharmaceuticals--
SLSSELLAS Life Sciences Group--

EYPT Revenue FAQ


EyePoint Pharmaceuticals's yearly revenue for 2023 was $46.02M, representing an increase of 11.14% compared to 2022. The company's yearly revenue for 2022 was $41.4M, representing an increase of 12.09% compared to 2021. EYPT's yearly revenue for 2021 was $36.94M, representing an increase of 7.27% compared to 2020.

EyePoint Pharmaceuticals's quarterly revenue for Q2 2024 was $9.48M, a -18.89% decrease from the previous quarter (Q1 2024), and a 4.09% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $11.68M, a -16.71% decrease from the previous quarter (Q4 2023), and a 52.08% increase year-over-year (Q1 2023). EYPT's quarterly revenue for Q4 2023 was $14.03M, a -7.72% decrease from the previous quarter (Q3 2023), and a 33.18% increase year-over-year (Q4 2022).

EyePoint Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 24.58%, and for the last 5 years (2019-2023) was 125.97%.

EyePoint Pharmaceuticals's revenue streams in c 22 are Y U T I Q Product, and D E X Y C U Product. Y U T I Q Product generated $28.33M in revenue, accounting 70.99% of the company's total revenue, up 67.04% year-over-year. D E X Y C U Product generated $11.58M in revenue, accounting 29.01% of the company's total revenue, down -36.93% year-over-year.

For the fiscal year ending Dec 22, the largest source of revenue of EyePoint Pharmaceuticals was Y U T I Q Product. This segment made a revenue of $28.33M, representing 70.99% of the company's total revenue.